Journal of Clinical Lipidology
Volume 2, Issue 6 , Pages 447-452 , December 2008

Combination thiazolidinedione and fibrate effect on high-density lipoprotein cholesterol (HDL-C) concentration in a Veterans Affairs patient population

Received 2 October 2008 ,Accepted 19 October 2008.

References 

  1. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999–2002. Diabetes Care. 2006;29:1263–1268
  2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  3. American Diabetes Association. Standards of medical care in diabetes—2008. Diabetes Care. 2008;31(suppl 1):S12–S54
  4. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled studies. BMJ. 2006;332:1115–1124
  5. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8–15
  6. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High-density lipoprotein as a protective factor against coronary heart disease: the Framingham study. Am J Med. 1977;62:707–714
  7. Frick MH, Elo O, Haapa K, et al. Helsinki Heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237–1245
  8. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641–651
  9. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410–418
  10. Sacks FM. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol. 2002;90:139–143
  11. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). BMJ. 1998;316:823–828
  12. Ebcioglu Z, Morgan J, Carey C, Capuzzi D. Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione. Ann Intern Med. 2003;139:e797–e798
  13. Sarker A, Semble RK, Dinneen SF, O'Rahilly S, Martin SC. Severe hypo-α-lipoproteinemia during treatment with rosiglitazone. Diabetes Care. 2004;27:2577–2580
  14. Senba H, Kawano M, Kawakami M. Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone. J Athero Throm. 2006;13:263–264
  15. Gutschi LM, Malcolm JC, Favreau CM, Ooi TC. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy. Ann Pharmacother. 2006;40:1672–1676
  16. Shetty C, Balasubramani M, Capps N, Milles J, Ramachandran S. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment. Diabetic Med. 2007;24:94–97
  17. Normen L, Frohlich J, Montaner J, et al. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care. 2004;27:2241–2242
  18. Keidar S, Guttmann , Stam T, Fishman I, Shapira C. High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate. Pharmacoepi Drug Saf. 2007;16:1192–1194
  19. Crook M, Lynas J, Wray R. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. J Clin Pathol. 2000;53:796–797
  20. Beghin L, Capps N, Duhal N, Davies J, Staels B, Luc G. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate. Ann Clin Biochem. 1999;36:523–525
  21. Collinson PO, Hjelm CJ, Canepo-Anson R. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate. Ann Clin Biochem. 1996;33:159–161
  22. Olukoga A. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. J Clin Pathol. 2002;55:718
  23. Oleesky D, Mir M. Paradoxical high-density lipoprotein reduction induced by fibrate therapy. Ann Clin Biochem. 1997;34:573–574
  24. Glaysher J, Van Heyningen C. Paradoxical decrease in high density lipoprotein-cholesterol associated with statin and fenofibrate combination therapy. Br J Diabetes Vasc Dis. 2007;7:295–297

PII: S1933-2874(08)00890-8

doi: 10.1016/j.jacl.2008.10.004

Journal of Clinical Lipidology
Volume 2, Issue 6 , Pages 447-452 , December 2008

Article Tools

* Image Usage & Resolution